L-carnitine is a small, water-soluble compound made in the body from the amino acids lysine and methionine. Its best-known job is moving long-chain fatty acids into the mitochondria, where they are broken down for energy. Because of that role, it is one of the most studied molecules in fatty-acid metabolism research.
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease.
Structure
| Property | Value |
|---|---|
| IUPAC name | (3R)-3-hydroxy-4-(trimethylazaniumyl)butanoate |
| Molecular formula | C₇H₁₅NO₃ |
| Molecular weight | ~161.2 g/mol |
| CAS number | 541-15-1 |
| PubChem CID | 10917 |
| Other names | Levocarnitine, (R)-carnitine, (−)-carnitine |
Only the L- (R-) form is biologically active. In its pure form, levocarnitine is a white, crystalline powder that takes up moisture from the air and dissolves readily in water.
Biological role
- The carnitine shuttle. The inner mitochondrial membrane does not let long-chain fatty acids pass on their own. Carnitine is attached to them (by carnitine palmitoyltransferase 1, CPT1) on the outer membrane, the resulting acylcarnitine is carried across, and carnitine palmitoyltransferase 2 (CPT2) releases the fatty acid inside the mitochondrion.
- Biosynthesis. The body makes carnitine from lysine and methionine in a four-step pathway; the last step is carried out by γ-butyrobetaine dioxygenase. In people on a typical diet, most carnitine comes from food rather than synthesis.
- Transport into cells. Cells take up carnitine through the OCTN2 transporter, encoded by the SLC22A5 gene. Defects in this transporter cause primary carnitine deficiency.
What research has looked at
- Fatty-acid oxidation and energy metabolism. How carnitine and its acyl esters (acylcarnitines) move fuel into mitochondria, in cell, tissue and whole-animal models.
- Inborn errors of metabolism. Primary carnitine deficiency (OCTN2 defects) and secondary deficiencies caused by other metabolic disorders. Acylcarnitine profiles are also used as research and screening markers for these disorders.
- Kidney disease and dialysis. Carnitine levels in people with end-stage renal disease on dialysis.
- Gut microbiome metabolism. Since a 2013 study in Nature Medicine (Koeth et al.), researchers have studied how gut bacteria convert carnitine to γ-butyrobetaine and then to trimethylamine (TMA) and TMAO, and how this relates to atherosclerosis in mouse models and to cardiovascular risk in human cohort data.
- Related esters. Acetyl-L-carnitine and propionyl-L-carnitine are studied as separate compounds with their own literature.
Regulatory context
Levocarnitine is an FDA-approved prescription drug (brand name Carnitor, also available as generics). The oral forms are labeled for primary systemic carnitine deficiency and for secondary carnitine deficiency caused by inborn errors of metabolism. The injectable form is also labeled for carnitine deficiency in patients with end-stage renal disease who are on dialysis. The product OmegAmino supplies is not a drug product and is sold strictly for laboratory research.
Limits of the evidence
- Much of the microbiome and TMAO work is from mouse models and observational human data. An association is not proof of cause.
- Results from one form (L-carnitine, acetyl-L-carnitine, propionyl-L-carnitine) do not automatically apply to the others.
Researchers should read the primary literature directly. PubMed lists the original studies under “carnitine” and “levocarnitine”.
Forms OmegAmino supplies
| Form | Amount |
|---|---|
| Solution | 30 mL at 600 mg/mL |
Every batch is third-party tested. You can look up the Certificate of Analysis for the L-carnitine we supply at omegamino-coas.com. Read more about how we test.
Storage
Store the solution sealed, away from light and heat. Follow the storage temperature on the label, and do not use it past the date on the vial.
Related research
- Glutathione, another solution in our range
- All research overviews
Researchers with an approved account can order from the shop.
